Gadget Island, Inc. is recalling 786 units of Pro Power Knight Plus, NUX Male Enhancement, and DYNAMITE SUPER capsules because they were found to be tainted with undeclared sildenafil and tadalafil. These ingredients are found in FDA-approved prescription drugs (such as Viagra and Cialis) for the treatment of male sexual enhancement, making these products unapproved drugs. The recall affects 1-count blister cards distributed nationwide in the USA.
The undeclared ingredients, sildenafil and tadalafil, can interact with nitrates found in some prescription drugs like nitroglycerin, potentially lowering blood pressure to dangerous or life-threatening levels. This is especially concerning for individuals with diabetes, high blood pressure, or heart disease.
You have 2 options:
Distributed by Beyond Health and youth Inc, Seattle, WA 98110
Distributed by SX Power CO., Chicago, Il 60612
Made in America
Front of Pro Power Knight Plus Capsule, 2550 mg
Back of Pro Power Knight Plus Capsule, 2550 mg
Front of NUX Male Enhancement Capsule
Back of NUX Male Enhancement Capsule
Front of DYNAMITE SUPER Capsule 58,000 mg
Back of DYNAMITE SUPER Capsule 58,000 mg
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.